Shots:

• CStone to receive $150M up front and $1.15B as milestones for both drugs along with royalties on each drug. EQRx get an exclusive right to lead global development and commercialization excluding Mainland China- Taiwan- Hong Kong- and Macau
• CStone retains rights to CS1003 in Greater China- where it will pursue development as a monothx. or as part of its combination strategy for the therapy
• Sugemalimab is an investigational anti-PD-L1 mAb and showed antitumor activity in multiple tumor types and was well-tolerated in P-I dose-escalation study in China. CS1003 is a humanized recombinant IgG4 mAb targeting PD-1- being developed for immunotherapy of various tumors

 ­ Ref: PRNewswire | Image: Under 30 CEO